Dr. Jatin Shah has served as Chief Medical Officer – Oncology of Sumitomo Pharma America since April 1, 2024. Prior to this role, he served as the Chief Oncology Development Officer since the Company’s formation in 2023, and as Executive Vice President, Chief Medical Officer and Global Head of Development of Sumitomo Pharma Oncology from 2022 to 2023. From 2017 to 2022, he served as Chief Medical Officer and Executive Vice President for Karyopharm Therapeutics, where he led the development of Xpovio and its approval in three indications. Previously, he worked at The University of Texas MD Anderson Cancer Center for nearly a decade, serving in the roles of Associate Professor and Associate Program Director of the Malignant Hematology Fellowship, as well as Director of Myeloma Clinical and Translational Research in the Department of Lymphoma/Myeloma, Division of Cancer Medicine. Dr. Shah received a B.S. in Mechanical Engineering and an M.D. from The Ohio State University. He holds board certification in hematology and oncology from the American Board of Internal Medicine. He has served as principal investigator/co-investigator for numerous relapsed/refractory multiple myeloma studies and has published articles and abstracts in many peer-reviewed journals.